Platelet aggregation in patients with CML in chronic phase receiving therapy with dasatinib or imatinib. Aggregation was recorded as increase in light transmission. Traces shown are representative of several independent tests with blood obtained from different patients treated with either dasatinib (A) or imatinib (B). Dasatinib was frequently associated with decreased response to arachidonic acid and epinephrine.